Mark Eisner - Mar 8, 2023 Form 4 Insider Report for FIBROGEN INC (FGEN)

Role
Chief Medical Officer
Signature
/s/ Cecelia Monoarfa-Taime, Attorney-in-fact
Stock symbol
FGEN
Transactions as of
Mar 8, 2023
Transactions value $
-$360,572
Form type
4
Date filed
3/10/2023, 08:55 PM
Previous filing
Mar 6, 2023
Next filing
Apr 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FGEN Common Stock Sale -$156K -7.36K -4.27% $21.16* 165K Mar 8, 2023 Direct F1
transaction FGEN Common Stock Award $0 +7.73K +4.68% $0.00 173K Mar 8, 2023 Direct F2
transaction FGEN Common Stock Award $0 +12.5K +7.2% $0.00 185K Mar 8, 2023 Direct F3
transaction FGEN Common Stock Sale -$78.5K -3.89K -2.1% $20.20* 181K Mar 10, 2023 Direct F4
transaction FGEN Common Stock Sale -$126K -6.26K -3.45% $20.20* 175K Mar 10, 2023 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
F2 Represents the number of shares released for PSU Milestone Grant vested on March 8, 2023.
F3 Represents the number of shares released for PSU TSR Grant vested on March 8, 2023.
F4 Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of PSU Milestone previously reported in Table I.
F5 Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of PSU TSR previously reported in Table I.